List of Excipients in Branded Drug FLEBOGAMMA

« Back to Dashboard

Flebogamma Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Flebogamma, particularly Flebogamma DIF 5% and 10%, uses a relatively simple excipient platform: human normal immunoglobulin stabilized primarily with glycine in water for injection. The formulation is preservative-free and avoids sucrose, which supports a renal-safety and hospital-use positioning. The main commercial opportunities are excipient supply, low-excipient immunoglobulin formulations, improved infusion compatibility, high-concentration delivery, and next-generation subcutaneous or long-acting immunoglobulin products.

What excipients are used in Flebogamma DIF?

Flebogamma DIF uses glycine as its principal stabilizing excipient. The finished product also contains water for injection. The formulation does not rely on sucrose, maltose, sorbitol, or human albumin as a stabilizer, according to product information from Grifols and European regulatory materials.[1][2]

Product	Immunoglobulin concentration	Principal excipient	Preservative status	Route
Flebogamma DIF 5%	50 mg/mL	Glycine	Preservative-free	Intravenous
Flebogamma DIF 10%	100 mg/mL	Glycine	Preservative-free	Intravenous

Glycine contributes to protein stability during manufacturing, storage, and administration. The formulation also uses controlled pH and osmolality specifications to maintain product quality and infusion tolerability.[1]

The excipient profile is strategically important because immunoglobulin products are highly sensitive to aggregation, fragmentation, oxidation, and changes in higher-order protein structure. Excipients must stabilize IgG without increasing infusion reactions, renal risk, hemolysis, or incompatibility with administration materials.

Why is glycine important in the Flebogamma formulation?

Glycine is a small amino acid used as a stabilizer in protein and plasma-derived products. In Flebogamma, it provides several formulation advantages:

• It supports IgG stability during storage.
• It avoids the renal-safety concerns historically associated with sucrose-containing intravenous immunoglobulin products.
• It has a long regulatory history in parenteral products.
• It does not add a carbohydrate load that may be commercially disadvantageous in patients with diabetes or metabolic risk.
• It supports a short excipient list that is easier to communicate to hospitals and infusion providers.

Glycine is not a substitute for process controls. Flebogamma’s quality profile also depends on cold-chain management, viral clearance, aggregate control, container closure, fill-finish conditions, and limits on biologically active contaminants.

The commercial value of glycine is therefore indirect. Glycine is widely available and usually represents a small portion of total product cost. The higher-value opportunity is supplying pharmaceutical-grade glycine with consistent impurity, endotoxin, bioburden, and particle-control specifications suitable for plasma-derived biologics.

How does Flebogamma compare with competing IVIG excipient strategies?

Flebogamma competes in a market where excipient selection affects renal warnings, infusion tolerability, shelf life, concentration, and prescribing preference.

Product or formulation strategy	Common stabilizer approach	Commercial implication
Flebogamma DIF	Glycine-based, sucrose-free	Simple excipient profile and renal-safety positioning
Sucrose-containing IVIG	Sucrose stabilization	Established platform but greater concern in renal-risk populations
Maltose-containing IVIG	Maltose stabilization	May create glucose-monitoring or assay-interference considerations
Proline-containing IVIG	L-proline stabilization	Alternative amino-acid platform
Sorbitol-containing IVIG	Sorbitol stabilization	Different tolerability and metabolic considerations
Albumin-containing products	Human albumin or related protein stabilizer	More complex biological excipient profile
Subcutaneous immunoglobulin	Often proline, glycine, polysorbate, or other stabilizer systems	Requires high local tolerability and controlled viscosity

The absence of sucrose is a meaningful commercial differentiator, although it does not eliminate all renal risk associated with high-dose intravenous immunoglobulin. Product selection remains dependent on dose, patient condition, hydration, renal function, infusion rate, and the broader safety profile.

What formulation patents protect Flebogamma?

Flebogamma is a plasma-derived biologic, and its commercial protection is not determined solely by a conventional small-molecule formulation patent. Relevant protection can arise from:

1. Manufacturing processes for plasma fractionation and IgG purification.
2. Viral inactivation and removal processes.
3. Methods for reducing aggregates and fragments.
4. Stabilized liquid IgG compositions.
5. Container, storage, and fill-finish controls.
6. Methods of treating immunodeficiency, ITP, CIDP, or other approved conditions.
7. Regulatory exclusivity associated with the biologics license.

The precise patent estate requires a jurisdiction-specific search of Grifols entities, related assignees, continuation applications, and patent-family members. Product labeling alone does not establish the full patent position.

Flebogamma does not have the same Orange Book framework used for FDA-approved small-molecule drugs. Biologic patent and exclusivity information is evaluated through the FDA Purple Book, the biologics license, relevant patent databases, and litigation records.[3][4]

Does Flebogamma have Orange Book-listed patents?

Flebogamma is not generally analyzed through Orange Book listings because it is a licensed biologic rather than a conventional small-molecule drug approved through an NDA. The more relevant regulatory concepts are:

• BLA approval and supplements.
• FDA reference-product designation.
• Twelve-year reference-product exclusivity under the Biologics Price Competition and Innovation Act.
• Biosimilar application and interchangeability pathways.
• Patent disclosures and certifications associated with biosimilar litigation.

A commercial review should not treat the absence of an Orange Book entry as evidence that Flebogamma has no patent protection.

When does Flebogamma lose exclusivity?

Flebogamma’s effective market protection depends on multiple layers of exclusivity rather than one expiration date.

Protection layer	Relevance to Flebogamma
Regulatory exclusivity	Depends on the reference product’s original biologics approval date and statutory treatment
Manufacturing patents	May cover purification, viral clearance, stabilization, or aggregate control
Formulation patents	May cover glycine concentration, pH, osmolality, or product stability
Method-of-use patents	May cover particular dosing or disease indications
Trade secrets	May protect plasma sourcing, process parameters, and quality controls
Supply barriers	Plasma collection and fractionation capacity can delay competitors

For an older plasma-derived product, practical competition may arrive through supply expansion, hospital contracting, and biosimilar or follow-on immunoglobulin products before a direct challenge to every manufacturing patent is resolved.

What generic or biosimilar entry risks exist for Flebogamma?

Traditional generic substitution does not apply to Flebogamma in the same way it applies to an oral tablet. A competing product would generally need to follow a biologics pathway or obtain approval as a separate biological product, depending on jurisdiction.

United States

A biosimilar applicant would need to demonstrate that the proposed product is highly similar to the reference product and has no clinically meaningful differences in safety, purity, and potency. The FDA may require analytical, pharmacokinetic, immunogenicity, and clinical evidence depending on the product and residual uncertainty.[3]

Flebogamma faces several barriers to rapid biosimilar entry:

• Human plasma source variability.
• Complex IgG subclass and antibody-repertoire characterization.
• Aggregate and fragment control.
• Viral safety validation.
• Comparability of excipient and container systems.
• Manufacturing scale and plasma availability.
• Hospital and payer contracting.
• Physician confidence in switching between immunoglobulin products.

Europe

The European Medicines Agency evaluates immunoglobulin products through a biologic quality framework. Competitors must demonstrate comparability, consistent viral safety, validated manufacturing, and clinical suitability for the proposed indications.[2]

Because IVIG products are not interchangeable based solely on active-ingredient identity, excipient differences can affect infusion protocols, tolerability, and institutional preference.

What commercial opportunities exist in Flebogamma excipients?

The largest near-term opportunity is not a new excipient itself. It is the supply and qualification infrastructure around a low-excipient, plasma-derived biologic.

Pharmaceutical-grade glycine supply

Suppliers can compete on:

• Low endotoxin specifications.
• Tight control of aldehydes, heavy metals, and related impurities.
• Reliable supply under pharmaceutical quality systems.
• Regional manufacturing redundancy.
• Documentation supporting biologics regulatory filings.
• Packaging suitable for bulk liquid formulation.

Glycine is a commodity-like excipient, so price alone is unlikely to create a durable advantage. The stronger proposition is qualified supply with validated consistency and dual-region capacity.

Alternative stabilizer platforms

Excipient companies can develop alternatives to glycine for next-generation immunoglobulin products. Candidate strategies include:

• Glycine and proline combinations.
• Low-concentration amino-acid systems.
• Nonreducing sugars with lower renal-risk positioning.
• Polyol systems optimized for high-concentration IgG.
• Surfactant-containing systems designed to reduce surface-induced aggregation.
• Buffer systems that preserve IgG at higher concentrations.

Any replacement must be tested for aggregation, subvisible particles, complement activation, immunogenicity, viscosity, infusion tolerability, and compatibility with tubing and bags.

High-concentration IVIG

The 10% presentation reduces infusion volume compared with 5% IVIG. This can improve treatment logistics for patients receiving large doses, including patients treated for ITP or inflammatory neuropathies.

High-concentration products create demand for excipient systems that control:

• Viscosity.
• Protein-protein interactions.
• Aggregate formation.
• Local tolerability during infusion.
• Stability after handling and dilution.
• Compatibility with pumps and administration sets.

This is a more valuable development area than simply reducing excipient count.

Subcutaneous immunoglobulin

Subcutaneous immunoglobulin products require different excipient priorities. The formulation must support repeated local administration, acceptable injection-site tolerability, manageable viscosity, and adequate shelf life. Hyaluronidase-enabled delivery adds another formulation and device-combination layer.

Potential opportunities include:

• Low-irritancy stabilizers.
• Viscosity-reducing excipient systems.
• Low-volume high-concentration formulations.
• Extended-use in-use stability.
• Device-compatible formulations.
• Excipient systems that reduce pain and swelling.

These products compete with IVIG on convenience and treatment-site economics rather than only on molecular composition.

What manufacturing and intellectual-property barriers protect Flebogamma?

The strongest barriers are likely to be manufacturing know-how and supply infrastructure rather than glycine ownership. Plasma-derived immunoglobulin manufacturing requires:

• Large-scale plasma collection.
• Donor screening and testing.
• Fractionation capacity.
• Viral inactivation and removal.
• Purification and chromatography.
• Aggregate reduction.
• Batch-to-batch consistency.
• Cold-chain distribution.
• Pharmacovigilance and immunoglobulin traceability.

These requirements create high capital and operational barriers. A competitor may be able to reproduce the excipient profile but still face years of process development and regulatory comparability work.

Trade secrets can be commercially significant where they concern chromatography conditions, purification yields, virus-clearance margins, stabilizer addition timing, filtration, and hold-time controls.

What is the FDA regulatory status of Flebogamma?

Flebogamma DIF is an FDA-regulated biologic marketed by Grifols, with product-specific labeling governing indications, concentrations, dosing, warnings, infusion rates, and storage.[1] Regulatory review should distinguish among:

• Flebogamma DIF 5%.
• Flebogamma DIF 10%.
• FDA-approved indications.
• Supplemental approvals.
• Manufacturing-site changes.
• Label revisions.
• Regional presentations outside the United States.

The product’s excipient strategy must remain consistent with the approved chemistry, manufacturing, and controls package. A change in glycine concentration, buffer, container, or stabilizer can require comparability work and a regulatory supplement.

Which companies challenge Flebogamma commercially?

Competition comes primarily from manufacturers of intravenous and subcutaneous immunoglobulin products rather than from generic-drug companies. Relevant competitors include CSL Behring, Takeda, Octapharma, Kedrion, ADMA Biologics, Biotest, Grifols, and other regional plasma-derived product manufacturers.

Competitive factor	Effect on Flebogamma
Plasma availability	Limits industry-wide production growth
Contract pricing	Drives hospital and specialty-pharmacy adoption
Excipient profile	Affects renal-risk and tolerability positioning
Concentration	Influences infusion time and volume
Indication breadth	Expands or restricts commercial utilization
Supply reliability	Can outweigh modest formulation differences
Biosimilar entry	May pressure price and contracting terms

The commercial moat is strongest when formulation performance is combined with reliable supply, broad indication coverage, and established infusion-center protocols.

How strong is the Flebogamma excipient strategy?

The excipient strategy is strong for a mature IVIG product because it is simple, clinically familiar, and aligned with a sucrose-free positioning. Its weaknesses are limited differentiation and low barriers to independently selecting glycine in a competing product.

Dimension	Assessment
Excipient simplicity	Strong
Renal-risk positioning	Favorable relative to sucrose-containing products
Cost advantage	Moderate
Patent differentiation	Likely limited at the excipient level
Manufacturing barrier	High
Biosimilar vulnerability	Moderate to high over the long term
Subcutaneous applicability	Requires a separate formulation strategy
Supplier leverage	Moderate because glycine is broadly available

The most defensible commercial opportunities are therefore process-linked: high-purity excipient supply, formulation analytics, aggregate control, high-concentration delivery, and next-generation immunoglobulin administration.

Key Takeaways

• Flebogamma DIF uses glycine and water for injection as its core excipient platform.
• The product is preservative-free and sucrose-free, supporting a differentiated renal-safety and hospital-use message.
• Glycine itself is unlikely to provide strong patent exclusivity because it is a widely used excipient.
• The stronger barriers are plasma supply, purification, viral clearance, aggregate control, regulatory comparability, and manufacturing know-how.
• Commercial opportunities include pharmaceutical-grade glycine supply, alternative stabilizers, high-concentration IVIG, subcutaneous immunoglobulin, viscosity control, and device-compatible formulations.
• Flebogamma is a biologic and should be assessed through BLA, Purple Book, biosimilar, manufacturing-patent, and trade-secret frameworks rather than a conventional Orange Book analysis.
• Biosimilar and follow-on immunoglobulin competition is a greater long-term pricing risk than a traditional small-molecule generic launch.

FAQs

Does Flebogamma contain sucrose?

No. Flebogamma DIF is formulated with glycine rather than sucrose as its principal stabilizer.[1][2]

Can glycine be replaced without a new regulatory review?

A change in glycine concentration or replacement with another stabilizer would require formal comparability and regulatory assessment because the change could affect IgG aggregation, potency, immunogenicity, and stability.

Is Flebogamma interchangeable with every other IVIG product?

No. IVIG products can differ in concentration, excipients, IgG characteristics, infusion rates, indications, and tolerability. Substitution decisions are product- and jurisdiction-specific.

Is Flebogamma a candidate for a traditional ANDA generic?

No. Flebogamma is a biologic product. A competing product would generally require a biologics approval pathway or another applicable biological-product route rather than a conventional ANDA pathway.

What is the highest-value excipient opportunity in Flebogamma-like products?

The highest-value opportunity is a qualified stabilizer and process platform that supports high-concentration IgG, low aggregation, low viscosity, strong in-use stability, and reliable regulatory comparability.

References

1. Grifols, S.A. (n.d.). Flebogamma DIF prescribing information. U.S. Food and Drug Administration.
2. European Medicines Agency. (n.d.). Flebogamma DIF: Summary of product characteristics. European Union medicines database.
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
4. U.S. Food and Drug Administration. (2020). Questions and answers on biosimilar development and the BPCI Act.